All In Biotech

Drug Trial Radar · NCT00014989

Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)

Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)

Last checked: Nov 20, 2026Latest source record: Jul 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,136

Actual

Start

Dec 1997

Primary completion

Feb 2007

Study completion Jun 2007

Sponsor

Lead sponsor
The George Washington University Biostatistics CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Apr 18, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

As many more premature infants survive, the numbers of these infants with health problems increases. The rate of cerebral palsy (CP) in extremely premature infants is approximately 20%. Magnesium sulfate, the most commonly used drug in the US to stop premature labor, may prevent CP. This trial tests whether magnesium sulfate given to a woman in labor with a premature fetus (24 to 31 weeks out of 40) will reduce the rate of death or moderate to severe CP in the children at 2 years. The children receive ultrasounds of their brains as infants and attend three follow-up visits over two years to assess their health and development.

Conditions

  • Cerebral Palsy
  • Intraventricular Hemorrhage
  • Periventricular Leukomalacia
  • Pulmonary Edema
  • Abruptio Placentae

Interventions

  • magnesium sulfateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite outcome of death or moderate to severe cerebral palsy

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Dept of OB/GYN, University of Miami

    Miami, Florida

  • Northwestern University

    Chicago, Illinois

  • Dept of OB/GYN, Hutzel Hospital

    Detroit, Michigan

  • St. Luke's - Roosevelt Hospital

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Forsyth Memorial Hospital, Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • The University Hospital, University of Cincinnati

    Cincinnati, Ohio

  • Case Western University

    Cleveland, Ohio

  • Dept of OB/GYN, Ohio State University

    Columbus, Ohio

  • MCP Hahnemann University

    Philadelphia, Pennsylvania

  • Dept of OB/GYN Magee Womens Hospital

    Pittsburgh, Pennsylvania

  • Women and Infants Hospital

    Providence, Rhode Island

  • Dept of OB/GYN, Southwestern Medical Center, University of Texas

    Dallas, Texas

  • University of Texas Medical Branch - Galveston

    Galveston, Texas

  • University of Texas - Houston

    Houston, Texas

  • University of Utah Medical Center

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.